Huons launches piogligtazone 15 mg

Huons says it has launched piogligtazone 15 mg, an oral antidiabetic agent that acts primarily by decreasing insulin resistance.

Piogligtazone is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus or adult-onset diabetes).

Pharmacological studies indicate that piogligtazone improves sensitivity to insulin in muscle and adipose tissue...